A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Convalescent Plasma Therapy for Covid-19: State of the Art
[post]
2020
unpublished
Preserved Fulltext
Convalescent blood product therapy has been introduced since early 1900s to treat emerging infectious disease based on the evidence that polyclonal neutralizing antibodies can reduce duration of viremia. Recent large outbreaks of viral diseases for whom effective antivirals or vaccines are still lacking has revamped the interest in convalescent plasma as life-saving treatments. This review summarizes historical settings of application, and surveys current technologies for collection,
doi:10.20944/preprints202004.0097.v2
fatcat:r4ag4mquinfxzavgx4sqlexkoe